# Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT06082167** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Exelixis** · enrollment: 600 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Zanzalintinib
- **DRUG:** Zanzalintinib-matched Placebo
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06082167
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-07
- **Primary completion:** 2028-08
- **Final completion:** 2029-03
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06082167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06082167, "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06082167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*